Sex-Based Differences in Clinical Outcomes Among Heart Failure Patients Treated With SGLT2 Inhibitors: Insights From a Multicenter Cohort Study
Abstract
Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a cornerstone in heart failure (HF) management across the spectrum of ejection fraction. However, evidence regarding potential sex-based differences in treatment response remains limited, particularly in real-world cohorts.
Methods: We conducted a retrospective cohort study including consecutive adult patients hospitalized with heart failure between 2019 and 2024 across five tertiary centers. Eligible patients initiated SGLT2i therapy (empagliflozin, dapagliflozin, or canagliflozin) within 90 days of index admission. Propensity score matching (1:1) was applied to balance baseline characteristics between men and women. The primary endpoint was all-cause mortality at two years. Secondary endpoints included heart failure rehospitalization, composite cardiovascular outcomes, and renal function trajectories. Kaplan–Meier survival analyses and multivariable Cox proportional hazards models were used to assess outcomes.
Results: A total of 4,286 patients were included (mean age 64 ± 12 years; 41% women). After matching, 1,512 men and 1,512 women were analyzed. Women demonstrated a significantly lower risk of all-cause mortality at two years compared to men (HR 0.78, 95% CI 0.65–0.92, p = 0.004). The reduction in HF rehospitalization was also more pronounced in women (HR 0.81, 95% CI 0.70–0.94, p = 0.006). No sex-based differences were observed in renal function decline. Sensitivity analyses across HF…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 4,286 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.